Gabelli Downgrades Ophthotech Corp (OPHT) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LITE
6. LYB
7. TFII
8. NVT
9. SPY
10. AAPL

Go back to Gabelli Downgrades Ophthotech Corp (OPHT) to Hold

Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration

December 12, 2016 1:00 AM EST

No benefit observed upon addition of Fovista® to monthly Lucentis® regimen for the treatment of wet age-related macular degeneration - Conference Call and Webcast Today, December 12, 2016 at 8:30 a.m. ET -

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Lucentis® (ranibizumab) anti-VEGF therapy... More